Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two major trials last month that found an older drug similar to Ozempic had no effect in slowing early-stage disease.
While GLP-1 drugs have…
Novo Nordisk still sees potential in Ozempic for Alzheimer’s, despite trial setbacks
